GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others.

Massachusetts Appeals Court·Decided June 22, 2026·No. 25-P-0435·Unpublished

Opinion

NOTICE: Summary decisions issued by the Appeals Court pursuant to M.A.C. Rule 23.0, as appearing in 97 Mass. App. Ct. 1017 (2020) (formerly known as rule 1:28, as amended by 73 Mass. App. Ct. 1001 [2009]), are primarily directed to the parties and, therefore, may not fully address the facts of the case or the panel's decisional rationale. Moreover, such decisions are not circulated to the entire court and, therefore, represent only the views of the panel that decided the case. A summary decision pursuant to rule 23.0 or rule 1:28 issued after February 25, 2008, may be cited for its persuasive value but, because of the limitations noted above, not as binding precedent. See Chace v. Curran, 71 Mass. App. Ct. 258, 260 n.4 (2008).

COMMONWEALTH OF MASSACHUSETTS

APPEALS COURT

25-P-435

GIUL, LLC

vs.

SHENGHUO MEDICAL, LLC, & others.1

MEMORANDUM AND ORDER PURSUANT TO RULE 23.0

GIUL, LLC (GIUL), invested $64,000 in Shenghuo Medical, LLC

(Shenghuo),2 with the understanding that Shenghuo would use the

funds to secure its own investment in Guided Therapeutics, Inc.

(GTI), the manufacturer and worldwide distributor of a medical

device known as LuViva (LuViva device).3 When the investment did

1Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein. Guided Therapeutics, Inc., was joined solely on reach and apply claims.

2Shenghuo later changed its name to K2 Medical. The judge and the parties referred to the company as Shenghuo and so do we.

3The LuViva device is a cervical cancer screening and diagnostic device which "uses spectroscopy to project light onto a woman's cervix, causing cells associated with cancer to fluoresce or to give other recognizable signals." not produce the return that GIUL and its owner, Paul Conte,

anticipated, GIUL sued Shenghuo and its managing members,

Michael J. Antonoplos, Richard P. Blumberg, and Mark L. Faupel.

GIUL also sued Shenghuo's legal counsel, Mark S. Pearlstein.

The majority of GIUL's claims, which were advanced in initial

and amended complaints, were dismissed or resolved in favor of

the defendants prior to the commencement of a bench trial on

claims arising from the Massachusetts Uniform Securities Act,

G. L. c. 110A, § 410 (a) (MUSA), and the Massachusetts Consumer

Protection Act, G. L. c. 93A, § 11 (c. 93A).4 The judge ruled in

favor of the defendants on all remaining claims after the bench

trial.

On appeal, GIUL argues, among other things, that the judge

applied an incorrect legal standard when he concluded that GIUL

failed to prove that the defendants did not disclose material

information about GTI's financial condition before GIUL made its

investment. We agree. We vacate the portion of the judgment on

the MUSA and c. 93A claims as to Shenghuo, Antonoplos, and

4 The procedural history of the litigation is set forth in the judge's findings and need not be repeated here. It suffices to note that GIUL's claims of fraud, breach of fiduciary duty, breach of contract, reach-and-apply claims, and conspiracy were disposed of on motions for judgment on the pleadings and summary judgment. GIUL makes no argument about these claims on appeal.

2 Blumberg, and remand for further proceedings consistent with

this memorandum and order. We otherwise affirm the judgment.

Background. We summarize the facts found by the judge as

articulated in his detailed findings. Faupel coinvented the

LuViva device, which, as noted, is manufactured by GTI. Faupel

served as chief executive officer of GTI from approximately 2008

through 2013, and again in 2023.5 Blumberg met Faupel around

2006 or 2007 and subsequently became a shareholder in GTI,

through which he gained familiarity with the LuViva device, its

intended use, and its international commercial prospects.

Blumberg reached out to entities that had experience in products

being marketed and used internationally. Ultimately, he

approached Antonoplos, who had served as chief executive officer

of a breast cancer diagnostics company.

Antonoplos was interested in the venture and, in February

2015, Antonoplos and Blumberg formed Shenghuo for the purpose of

obtaining licensing rights from GTI, raising capital from

investors, and distributing the LuViva device throughout Asia.

In the beginning, Antonoplos and Blumberg were the sole managing

members of Shenghuo and exercised full control over its

5 From 2013 to 2015, Faupel worked as a consultant for GTI and then joined its board of directors in 2016.

3 operations. Soon thereafter, Faupel and Pearlstein became

members of Shenghuo as well.

In June 2016, Shenghuo entered into a licensing agreement

with GTI in which GTI gave Shenghuo a $200,000 conditional loan.

Under the agreement, GTI was obligated to repay the loan only if

it obtained at least $1 million in additional financing within a

specified timeframe. If GTI failed to obtain such financing, it

would not incur a repayment obligation, but the agreement

allowed for the possibility that any investment from Shenghuo

could be converted into GTI common stock.

Within weeks of signing the licensing agreement with GTI,

Shenghuo raised approximately $136,000 and sought additional

capital to meet the $200,000 investment requirement. Other

investors included John Imhoff and Stephen Maloof.6 Both of them

had ownership interests in GTI and made investments under

subscription agreements drafted by Pearlstein.7 Blumberg

communicated with these investors directly and explained that

repayment depended on GTI's success in raising funds.

6 Maloof had his spouse make the investment on his behalf.

7 These agreements provided that repayment would occur only if GTI obtained financing and that investors would retain their equity interest even if repayment occurred.

4 At about the same time, Antonoplos reached out to Conte,

who owns and controls GIUL.8 Antonoplos called Conte in June

2016 to solicit investments. The judge found that during this

conversation Antonoplos made clear to Conte that Shenghuo had no

present income and that its only "real asset was its licens[ing]

agreement with GTI." Antonoplos informed Conte that he had

already helped raise approximately $136,000 and said that

Shenghuo needed an additional $64,000 to complete its funding

obligations. Antonoplos further explained in "general terms

that anyone willing to invest the remaining $64,000 would

receive an ownership interest in Shenghuo as well as a

conditional right to repayment of the investment amount." The

judge found that Antonoplos told Conte that repayment of the

investment "was contingent on GTI raising an additional $1

million and then repaying Shenghuo," and that Antonoplos "never

told Conte that repayment would be guaranteed or that there

would be any deadline by which Shenghuo would be required to

repay this investment." During this same conversation, Conte

asked Antonoplos to send him an e-mail message summarizing the

investment opportunity.

8 Conte and Antonoplos had known each other for about ten years and spoke with each other by phone several times a week. Conte had decades of professional experience with financial transactions and investments as well as a law degree.

5 As requested, on June 9, 2016, Antonoplos followed up in an

e-mail message to Conte.

Free access — add to your briefcase to read the full text and ask questions with AI

GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others., (Mass. Ct. App. 2026).

GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others. (GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Patry v. Liberty Mobilehome Sales, Inc.
475 N.E.2d 392 (Massachusetts Supreme Judicial Court, 1985)
Demoulas v. Demoulas Super Markets, Inc.
677 N.E.2d 159 (Massachusetts Supreme Judicial Court, 1997)
Marram v. Kobrick Offshore Fund, Ltd.
442 Mass. 43 (Massachusetts Supreme Judicial Court, 2004)
Chace v. Curran
881 N.E.2d 792 (Massachusetts Appeals Court, 2008)
Helwig v. Vencor, Inc.
251 F.3d 540 (Sixth Circuit, 2001)